{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:33:33Z","timestamp":1773455613630,"version":"3.50.1"},"reference-count":75,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2020,8,10]]},"abstract":"<jats:sec><jats:title\/><jats:p>Patients with rheumatoid diseases have an increased risk of cardiovascular disease (CVD) and CVD-related death compared with the general population. Both the traditional cardiovascular risk factors and systemic inflammation are contributors to this phenomenon. This review examines the available evidence about the effects of synthetic, non-biologic disease-modifying antirheumatic drugs (DMARDs) on CVD risk. This is an important issue for clinicians when deciding on individual treatment plans in patients with rheumatic diseases. Evidence suggests that synthetic, non-biologic DMARDs such as methotrexate, sulfasalazine, hydroxychloroquine, leflunomide and tofacitinib show decreased CVD morbidity and mortality. However, the strongest data in favour of a reduction in CVD events in rheumatoid patients are shown with methotrexate, which has been the focus of most studies. Adequate proof for a favourable effect also exists for hydroxychloroquine. Larger, prospective studies and randomized clinical trials are needed to better characterize the effect of synthetic, non-biologic DMARDs on CVD outcomes in these patients. Design of future studies should include areas with lack of evidence, such as the risk for heart failure, arrhythmias and valvular heart disease. The clinically relevant question whether synthetic, non-biologic DMARDs are inferior to biologic DMARDs in terms of CVD outcomes remains not adequately addressed.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1570161117666190930113837","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T11:45:31Z","timestamp":1569843931000},"page":"455-462","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs)"],"prefix":"10.2174","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9670-5886","authenticated-orcid":true,"given":"Iordanis S.","family":"Mourouzis","sequence":"first","affiliation":[{"name":"Department of Pharmacology, School of Medicine, National and Kapodistrian University of Athens, Athens 11527, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0336-4745","authenticated-orcid":true,"given":"Antonis S.","family":"Manolis","sequence":"additional","affiliation":[{"name":"Third Department of Cardiology, Athens University School of Medicine, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2449-0991","authenticated-orcid":true,"given":"Constantinos","family":"Pantos","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Medicine, National and Kapodistrian University of Athens, Athens 11527, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/rheumatology\/kep252","volume":"48","author":"Meune C.","year":"2009","unstructured":"Meune C.; Touz\u00e9 E.; Trinquart L.; Allanore Y.; Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a system-atic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2009,48(10),1309-1313","journal-title":"Rheumatology (Oxford)"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/ard.2009.113696","volume":"69","author":"Peters M.J.","year":"2010","unstructured":"Peters M.J.; Symmons D.P.; McCarey D.; EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010,69(2),325-331","journal-title":"Ann Rheum Dis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/art.24092","volume":"59","author":"Avi\u00f1a-Zubieta J.A.","year":"2008","unstructured":"Avi\u00f1a-Zubieta J.A.; Choi H.K.; Sadatsafavi M.; Etminan M.; Esdaile J.M.; Lacaille D.; Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008,59(12),1690-1697","journal-title":"Arthritis Rheum"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/j.ijcard.2012.05.057","volume":"167","author":"Corrao S.","year":"2013","unstructured":"Corrao S.; Messina S.; Pistone G.; Calvo L.; Scaglione R.; Licata G.; Heart involvement in rheumatoid arthritis: systematic review and meta-analysis. Int J Cardiol 2013,167(5),2031-2038","journal-title":"Int J Cardiol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1136\/ard.2010.143396","volume":"70","author":"Lindhardsen J.","year":"2011","unstructured":"Lindhardsen J.; Ahlehoff O.; Gislason G.H.; The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011,70(6),929-934","journal-title":"Ann Rheum Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1136\/ard.2009.126128","volume":"69","author":"Semb A.G.","year":"2010","unstructured":"Semb A.G.; Kvien T.K.; Aastveit A.H.; Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study. Ann Rheum Dis 2010,69(11),1996-2001","journal-title":"Ann Rheum Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1093\/rheumatology\/keu224","volume":"53","author":"Choy E.","year":"2014","unstructured":"Choy E.; Ganeshalingam K.; Semb A.G.; Szekanecz Z.; Nurmohamed M.; Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) 2014,53(12),2143-2154","journal-title":"Rheumatology (Oxford)"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1002\/art.21932","volume":"54","author":"Van Doornum S.","year":"2006","unstructured":"Van Doornum S.; Brand C.; King B.; Sundararajan V.; Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis. Arthritis Rheum 2006,54(7),2061-2068","journal-title":"Arthritis Rheum"},{"key":"ref=9","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12915","volume":"48","author":"L\u00f8gstrup B.B.","year":"2018","unstructured":"L\u00f8gstrup B.B.; Ellingsen T.; Pedersen A.B.; Kjaersgaard A.; B\u00f8tker H.E.; Maeng M.; Development of heart failure in patients with rheumatoid arthritis: A Danish population-based study. Eur J Clin Invest 2018,48(5)","journal-title":"Eur J Clin Invest"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/art.20855","volume":"52","author":"Nicola P.J.","year":"2005","unstructured":"Nicola P.J.; Maradit-Kremers H.; Roger V.L.; The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005,52(2),412-420","journal-title":"Arthritis Rheum"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.amjmed.2003.09.039","volume":"116","author":"Wolfe F.","year":"2004","unstructured":"Wolfe F.; Michaud K.; Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004,116(5),305-311","journal-title":"Am J Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1002\/art.21349","volume":"52","author":"Crowson C.S.","year":"2005","unstructured":"Crowson C.S.; Nicola P.J.; Kremers H.M.; How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? Arthritis Rheum 2005,52(10),3039-3044","journal-title":"Arthritis Rheum"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.amjcard.2007.03.048","volume":"100","author":"Roldan C.A.","year":"2007","unstructured":"Roldan C.A.; DeLong C.; Qualls C.R.; Crawford M.H.; Characterization of valvular heart disease in rheumatoid arthritis by transesophageal echo-cardiography and clinical correlates. Am J Cardiol 2007,100(3),496-502","journal-title":"Am J Cardiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/138161211795049796","volume":"17","author":"Miller A.M.","year":"2011","unstructured":"Miller A.M.; McInnes I.B.; Cytokines as therapeutic targets to reduce cardiovascular risk in chronic inflammation. Curr Pharm Des 2011,17(1),1-8","journal-title":"Curr Pharm Des"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1161\/01.CIR.0000125700.33637.B1","volume":"109","author":"Waehre T.","year":"2004","unstructured":"Waehre T.; Yndestad A.; Smith C.; Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation 2004,109(16),1966-1972","journal-title":"Circulation"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/art.25009","volume":"61","author":"Rho Y.H.","year":"2009","unstructured":"Rho Y.H.; Chung C.P.; Oeser A.; Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009,61(11),1580-1585","journal-title":"Arthritis Rheum"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1136\/annrheumdis-2017-212597","volume":"77","author":"Ntari L.","year":"2018","unstructured":"Ntari L.; Sakkou M.; Chouvardas P.; Comorbid TNF-mediated heart valve disease and chronic polyarthritis share common mesenchymal cell-mediated aetiopathogenesis. Ann Rheum Dis 2018,77(6),926-934","journal-title":"Ann Rheum Dis"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s12016-016-8566-3","volume":"52","author":"Laz\u00farov\u00e1 I.","year":"2017","unstructured":"Laz\u00farov\u00e1 I.; Tom\u00e1\u0161 \u013d.; Cardiac impairment in rheumatoid arthritis and influence of anti-TNF\u03b1 treatment. Clin Rev Allergy Immunol 2017,52(3),323-332","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1136\/annrheumdis-2016-209562","volume":"76","author":"Lacaille D.","year":"2017","unstructured":"Lacaille D.; Avina-Zubieta J.A.; Sayre E.C.; Abrahamowicz M.; Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap. Ann Rheum Dis 2017,76(6),1057-1063","journal-title":"Ann Rheum Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/annrheumdis-2016-210997","volume":"76","author":"Arts E.E.","year":"2017","unstructured":"Arts E.E.; Fransen J.; Den Broeder A.A.; van Riel P.L.C.M.; Popa C.D.; Low disease activity (DAS28\u22643.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study. Ann Rheum Dis 2017,76(10),1693-1699","journal-title":"Ann Rheum Dis"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"Roubille C.","year":"2015","unstructured":"Roubille C.; Richer V.; Starnino T.; The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015,74(3),480-489","journal-title":"Ann Rheum Dis"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2016.175","volume":"12","author":"Brown P.M.","year":"2016","unstructured":"Brown P.M.; Pratt A.G.; Isaacs J.D.; Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol 2016,12(12),731-742","journal-title":"Nat Rev Rheumatol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1515\/cclm.1993.31.10.667","volume":"31","author":"Brody M.","year":"1993","unstructured":"Brody M.; B\u00f6hm I.; Bauer R.; Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin 1 beta to the interleukin 1 receptor on target cells. Eur J Clin Chem Clin Biochem 1993,31(10),667-674","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"ref=24","unstructured":"Methotrexate Side Effects in Detail"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.4236\/ojpathology.2013.34030","volume":"3","author":"Yoshino T.","year":"2013","unstructured":"Yoshino T.; Nishida H.; Takita T.; A report of 2 cases of disseminated invasive aspergillosis with myocarditis in immunocompromised patients. Open J Pathol 2013,3,166-169","journal-title":"Open J Pathol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","volume":"359","author":"Choi H.K.","year":"2002","unstructured":"Choi H.K.; Hern\u00e1n M.A.; Seeger J.D.; Robins J.M.; Wolfe F.; Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002,359(9313),1173-1177","journal-title":"Lancet"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/rheumatology\/kep366","volume":"49","author":"Westlake S.L.","year":"2010","unstructured":"Westlake S.L.; Colebatch A.N.; Baird J.; The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010,49(2),295-307","journal-title":"Rheumatology (Oxford)"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"R151","DOI":"10.1186\/ar2045","volume":"8","author":"van Halm V.P.","year":"2006","unstructured":"van Halm V.P.; Nurmohamed M.T.; Twisk J.W.; Dijkmans B.A.; Voskuyl A.E.; Disease-modifying antirheumatic drugs are associated with a re-duced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006,8(5),R151","journal-title":"Arthritis Res Ther"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jaad.2004.06.017","volume":"52","author":"Prodanovich S.","year":"2005","unstructured":"Prodanovich S.; Ma F.; Taylor J.R.; Pezon C.; Fasihi T.; Kirsner R.S.; Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005,52(2),262-267","journal-title":"J Am Acad Dermatol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","volume":"108","author":"Micha R.","year":"2011","unstructured":"Micha R.; Imamura F.; Wyler von Ballmoos M.; Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011,108(9),1362-1370","journal-title":"Am J Cardiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/art.22094","volume":"55","author":"Suissa S.","year":"2006","unstructured":"Suissa S.; Bernatsky S.; Hudson M.; Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 2006,55(4),531-536","journal-title":"Arthritis Rheum"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1093\/rheumatology\/keh610","volume":"44","author":"Bernatsky S.","year":"2005","unstructured":"Bernatsky S.; Hudson M.; Suissa S.; Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 2005,44(5),677-680","journal-title":"Rheumatology (Oxford)"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.semarthrit.2008.02.001","volume":"38","author":"Gonzalez-Gay M.A.","year":"2008","unstructured":"Gonzalez-Gay M.A.; Gonzalez-Juanatey C.; Vazquez-Rodriguez T.R.; Martin J.; Llorca J.; Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis. Semin Arthritis Rheum 2008,38(2),67-70","journal-title":"Semin Arthritis Rheum"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1002\/art.24040","volume":"58","author":"Reiss A.B.","year":"2008","unstructured":"Reiss A.B.; Carsons S.E.; Anwar K.; Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte\/macrophages. Arthritis Rheum 2008,58(12),3675-3683","journal-title":"Arthritis Rheum"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/art.39039","volume":"67","author":"Ronda N.","year":"2015","unstructured":"Ronda N.; Greco D.; Adorni M.P.; Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. Arthritis Rheumatol 2015,67(5),1155-1164","journal-title":"Arthritis Rheumatol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","volume":"380","author":"Ridker P.M.","year":"2019","unstructured":"Ridker P.M.; Everett B.M.; Pradhan A.; Low-Dose methotrexate for the prevention of atherosclerotic events. N Engl J Med CIRT investigators2019,380(8),752-762","journal-title":"N Engl J Med"},{"key":"ref=37","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212557","volume":"7","author":"Mangoni A.A.","year":"2018","unstructured":"Mangoni A.A.; Tommasi S.; Zinellu A.; Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate. Drugs Context 2018,7","journal-title":"Drugs Context"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/1759720X17719850","volume":"9","author":"Mangoni A.A.","year":"2017","unstructured":"Mangoni A.A.; Baghdadi L.R.; Shanahan E.M.; Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study. Ther Adv Musculoskelet Dis 2017,9(9),213-229","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1136\/ard.2005.050377","volume":"65","author":"Solomon D.H.","year":"2006","unstructured":"Solomon D.H.; Goodson N.J.; Katz J.N.; Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006,65(12),1608-1612","journal-title":"Ann Rheum Dis"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.autrev.2010.07.018","volume":"9","author":"Atzeni F.","year":"2010","unstructured":"Atzeni F.; Turiel M.; Caporali R.; The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun Rev 2010,9(12),835-839","journal-title":"Autoimmun Rev"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3899\/jrheum.180427","volume":"46","author":"Widdifield J.","year":"2019","unstructured":"Widdifield J.; Abrahamowicz M.; Paterson J.M.; Associations between methotrexate use and the risk of cardiovascular events in patients with elderly-onset rheumatoid arthritis. J Rheumatol 2019,46(5),467-474","journal-title":"J Rheumatol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"R30","DOI":"10.1186\/ar2383","volume":"10","author":"Naranjo A.","year":"2008","unstructured":"Naranjo A.; Sokka T.; Descalzo M.A.; Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther QUEST-RA Group2008,10(2),R30","journal-title":"Arthritis Res Ther"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/1756-185X.12986","volume":"20","author":"Tam H.W.","year":"2017","unstructured":"Tam H.W.; Yeo K.J.; Leong P.Y.; Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study. Int J Rheum Dis 2017,20(3),363-370","journal-title":"Int J Rheum Dis"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2174\/138161212799504759","volume":"18","author":"Gasparyan A.Y.","year":"2012","unstructured":"Gasparyan A.Y.; Ayvazyan L.; Cocco G.; Kitas G.D.; Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. Curr Pharm Des 2012,18(11),1543-1555","journal-title":"Curr Pharm Des"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0049-0172(10)80012-5","volume":"23","author":"Fox R.I.","year":"1993","unstructured":"Fox R.I.; Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993,23(2)(Suppl. 1),82-91","journal-title":"Semin Arthritis Rheum"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1182\/blood-2008-03-144204","volume":"112","author":"Rand J.H.","year":"2008","unstructured":"Rand J.H.; Wu X.X.; Quinn A.S.; Chen P.P.; Hathcock J.J.; Taatjes D.J.; Hydroxychloroquine directly reduces the binding of antiphospholipid an-tibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 2008,112(5),1687-1695","journal-title":"Blood"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1002\/acr.22341","volume":"66","author":"Kerr G.","year":"2014","unstructured":"Kerr G.; Aujero M.; Richards J.; Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. Arthritis Care Res (Hoboken) 2014,66(11),1619-1626","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0022-2275(20)37596-9","volume":"37","author":"Lange Y.","year":"1996","unstructured":"Lange Y.; Duan H.; Mazzone T.; Cholesterol homeostasis is modulated by amphiphiles at transcriptional and post-transcriptional loci. J Lipid Res 1996,37(3),534-539","journal-title":"J Lipid Res"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.cmet.2006.10.002","volume":"4","author":"Schneider J.G.","year":"2006","unstructured":"Schneider J.G.; Finck B.N.; Ren J.; ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab 2006,4(5),377-389","journal-title":"Cell Metab"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1136\/ard.56.6.374","volume":"56","author":"Munro R.","year":"1997","unstructured":"Munro R.; Morrison E.; McDonald A.G.; Hunter J.A.; Madhok R.; Capell H.A.; Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997,56(6),374-377","journal-title":"Ann Rheum Dis"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/RHU.0b013e318214b6b5","volume":"17","author":"Bili A.","year":"2011","unstructured":"Bili A.; Sartorius J.A.; Kirchner H.L.; Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. J Clin Rheumatol 2011,17(3),115-120","journal-title":"J Clin Rheumatol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jama.298.2.187","volume":"298","author":"Wasko M.C.","year":"2007","unstructured":"Wasko M.C.; Hubert H.B.; Lingala V.B.; Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007,298(2),187-193","journal-title":"JAMA"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/art.27289","volume":"62","author":"Jung H.","year":"2010","unstructured":"Jung H.; Bobba R.; Su J.; The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010,62(3),863-868","journal-title":"Arthritis Rheum"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3899\/jrheum.090994","volume":"37","author":"Penn S.K.","year":"2010","unstructured":"Penn S.K.; Kao A.H.; Schott L.L.; Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 2010,37(6),1136-1142","journal-title":"J Rheumatol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1002\/art.27703","volume":"62","author":"Rekedal L.R.","year":"2010","unstructured":"Rekedal L.R.; Massarotti E.; Garg R.; Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. Arthritis Rheum 2010,62(12),3569-3573","journal-title":"Arthritis Rheum"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0168-8227(01)00325-4","volume":"55","author":"Gerstein H.C.","year":"2002","unstructured":"Gerstein H.C.; Thorpe K.E.; Taylor D.W.; Haynes R.B.; The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial. Diabetes Res Clin Pract 2002,55(3),209-219","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1042\/bj3110787","volume":"311","author":"Bevan A.P.","year":"1995","unstructured":"Bevan A.P.; Christensen J.R.; Tikerpae J.; Smith G.D.; Chloroquine augments the binding of insulin to its receptor. Biochem J 1995,311(Pt 3),787-795","journal-title":"Biochem J"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1529-8019.2007.00131.x","volume":"20","author":"Kalia S.","year":"2007","unstructured":"Kalia S.; Dutz J.P.; New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007,20(4),160-174","journal-title":"Dermatol Ther"},{"key":"ref=59","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002867","volume":"5","author":"Sharma T.S.","year":"2016","unstructured":"Sharma T.S.; Wasko M.C.; Tang X.; Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J Am Heart Assoc 2016,5(1)","journal-title":"J Am Heart Assoc"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s10067-017-3596-7","volume":"36","author":"Li C.","year":"2017","unstructured":"Li C.; Wang X.R.; Ji H.J.; Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China. Clin Rheumatol 2017,36(5),1023-1029","journal-title":"Clin Rheumatol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.2147\/DDDT.S166893","volume":"12","author":"Liu D.","year":"2018","unstructured":"Liu D.; Li X.; Zhang Y.; Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. Drug Des Devel Ther 2018,12,1685-1695","journal-title":"Drug Des Devel Ther"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/ard.2008.101766","volume":"69","author":"Ruiz-Irastorza G.","year":"2010","unstructured":"Ruiz-Irastorza G.; Ramos-Casals M.; Brito-Zeron P.; Khamashta M.A.; Clinical efficacy and side effects of antimalarials in systemic lupus er-ythematosus: a systematic review. Ann Rheum Dis 2010,69(1),20-28","journal-title":"Ann Rheum Dis"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/rheumatology\/kel402","volume":"46","author":"Costedoat-Chalumeau N.","year":"2007","unstructured":"Costedoat-Chalumeau N.; Hulot J.S.; Amoura Z.; Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardio-grams in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology (Oxford) 2007,46(5),808-810","journal-title":"Rheumatology (Oxford)"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.euje.2006.02.002","volume":"8","author":"Cotroneo J.","year":"2007","unstructured":"Cotroneo J.; Sleik K.M.; Rene Rodriguez E.; Klein A.L.; Hydroxychloroquine-induced restrictive cardiomyopathy. Eur J Echocardiogr 2007,8(4),247-251","journal-title":"Eur J Echocardiogr"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.echo.2004.09.029","volume":"18","author":"Naqvi T.Z.","year":"2005","unstructured":"Naqvi T.Z.; Luthringer D.; Marchevsky A.; Saouf R.; Gul K.; Buchbinder N.A.; Chloroquine-induced cardiomyopathy-echocardiographic features. J Am Soc Echocardiogr 2005,18(4),383-387","journal-title":"J Am Soc Echocardiogr"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/03007995.2018.1492910","volume":"35","author":"Hung Y.M.","year":"2019","unstructured":"Hung Y.M.; Lin L.; Wang Y.H.; Wei J.C.; Wang P.Y.; Chiou J.Y.; Combination effect of anti-rheumatic medications for coronary artery diseases risk in rheumatoid arthritis: a nationwide population-based cohort study. Curr Med Res Opin 2019,35(2),313-320","journal-title":"Curr Med Res Opin"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.mehy.2006.10.036","volume":"68","author":"Minoretti P.","year":"2007","unstructured":"Minoretti P.; Bruno A.; Di Vito C.; Emanuele E.; Leflunomide as an antiatherogenic drug. Med Hypotheses 2007,68(5),1175-1176","journal-title":"Med Hypotheses"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2165\/00003495-200262110-00003","volume":"62","author":"Nurmohamed M.T.","year":"2002","unstructured":"Nurmohamed M.T.; van Halm V.P.; Dijkmans B.A.; Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. Drugs 2002,62(11),1599-1609","journal-title":"Drugs"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/ard.61.6.567","volume":"61","author":"Rozman B.","year":"2002","unstructured":"Rozman B.; Praprotnik S.; Logar D.; Leflunomide and hypertension. Ann Rheum Dis 2002,61(6),567-569","journal-title":"Ann Rheum Dis"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/1744666X.2019.1607298","volume":"15","author":"Yamaoka K.","year":"2019","unstructured":"Yamaoka K.; Tofacitinib for the treatment of rheumatoid arthritis: an update. Expert Rev Clin Immunol 2019,15(6),577-588","journal-title":"Expert Rev Clin Immunol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"van Vollenhoven R.F.","year":"2012","unstructured":"van Vollenhoven R.F.; Fleischmann R.; Cohen S.; Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med ORAL Standard Investigators2012,367(6),508-519","journal-title":"N Engl J Med"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/annrheumdis-2012-202442","volume":"73","author":"McInnes I.B.","year":"2014","unstructured":"McInnes I.B.; Kim H.Y.; Lee S.H.; Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis 2014,73(1),124-131","journal-title":"Ann Rheum Dis"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/annrheumdis-2011-200493","volume":"71","author":"Charles-Schoeman C.","year":"2012","unstructured":"Charles-Schoeman C.; Wicker P.; Sechtem U.; Cardiovascular safety findings in rheumatoid arthritis patients treated with tofacitinib (CP-690,550), a novel oral JAK inhibitor. Ann Rheum Dis 2012,71,201","journal-title":"Ann Rheum Dis"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","volume":"46","author":"Charles-Schoeman C.","year":"2016","unstructured":"Charles-Schoeman C.; Wicker P.; Gonzalez-Gay M.A.; Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum 2016,46(3),261-271","journal-title":"Semin Arthritis Rheum"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00296-010-1446-x","volume":"31","author":"Gasparyan A.Y.","year":"2011","unstructured":"Gasparyan A.Y.; Stavropoulos-Kalinoglou A.; Mikhailidis D.P.; Douglas K.M.; Kitas G.D.; Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int 2011,31(2),153-164","journal-title":"Rheumatol Int"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/175205","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/175205\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/175205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T19:00:52Z","timestamp":1611428452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/175205\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,8,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570161117666190930113837","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-05-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}